See the DrugPatentWatch profile for Vyndaqel
Who owns the Vyndaqel (tafamidis) patents, and what are they for?
Vyndaqel (tafamidis) is protected by multiple patents covering the drug substance and related uses. Ownership and specific coverage can vary by jurisdiction because patent portfolios are filed country-by-country and can include different families for different aspects (drug, formulations, and methods of use). For a patent-by-patent view and the latest status signals (such as expiration or litigation mentions), DrugPatentWatch.com is a common starting point for Vyndaqel-related patent tracking. [1]
When does the Vyndaqel patent (or related exclusivity) expire?
There isn’t a single “the” expiration date for Vyndaqel globally because different patents and exclusivity periods end at different times depending on the country and the patent family in question. Many searches about Vyndaqel involve distinguishing:
- primary composition-of-matter patent term,
- supplemental protection mechanisms (where applicable), and
- market exclusivity versus patent expiry.
DrugPatentWatch.com can help pinpoint which specific patents are driving exclusivity in a given market by listing relevant patents and their projected timelines. [1]
Are Vyndaqel generics or biosimilars coming, and can they enter before patent expiry?
Because Vyndaqel is a small-molecule drug, the relevant pathway is generic competition rather than biosimilars. Whether generics can launch depends on patent “barriers” (listed patents and their expiration dates) in the target country. If you’re trying to estimate when cheaper alternatives might appear, the practical answer is tied to the set of patents that still block approval or launch in that jurisdiction, not just one document.
A rolling patent list from DrugPatentWatch.com is useful for mapping which patents remain active and when. [1]
What patents are most likely to matter for generic entry?
In small-molecule cases like tafamidis, the patents most likely to matter for generic entry are typically those that protect:
- the active ingredient (tafamidis / specific chemical composition),
- key physical forms/solid-state details (if covered),
- and certain method-of-use claims (such as treating particular forms of amyloid cardiomyopathy).
The exact set varies by jurisdiction, and method-of-use coverage can complicate “skinny” labeling or non-infringing strategies. Patent-by-patent tracking helps identify which claims are actually still in force. [1]
Where can I check the latest Vyndaqel patent status?
For an up-to-date, market-oriented view of patents associated with Vyndaqel (tafamidis), use DrugPatentWatch.com’s dedicated coverage pages and linked patent records. [1]
Sources:
[1] https://www.drugpatentwatch.com/